JPMHC 2022

JPM 2022: Bluebird bio hopes for clear skies ahead as it gears up for trio of gene therapy launches
Fierce Pharma
Thu, 01/13/22 - 10:32 pm
JPMHC 2022
Bluebird Bio
gene therapy
sickle cell disease
beti-cel
JPM22, Day 4: Vertex aims to be cystic fibrosis leader into the 2030s; Gritstone hopes for new colorectal cancer biomarker
Fierce Biotech
Thu, 01/13/22 - 11:12 am
JPMHC 2022
Vertex Pharmaceuticals
Gritstone Bio
JPM 2022: Novartis rewrites the drug launch playbook with Leqvio, and it doesn't plan to stop there, exec says
Fierce Pharma
Thu, 01/13/22 - 11:06 am
JPMHC 2022
Novartis
Leqvio
drug launches
Regeneron
Amgen
Sanofi
JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of $15B
Fierce Pharma
Thu, 01/13/22 - 11:00 am
AbbVie
Rinvoq
Skyrizi
JPMHC 2022
JPM22, Day 3: In short order, Perrigo part of a new landscape; Legend, J&J prep for cilta-cel launch
Fierce Pharma
Wed, 01/12/22 - 11:22 pm
JPMHC 2022
Bausch Health
Amgen
Eli Lilly
Perrigo
JNJ
Legend Biotech
JPM22, Day 3: BeiGene, Ionis promise 'tidal wave' of new drugs; Roche launches smart, point-of-care glucose monitor
Fierce Biotech
Wed, 01/12/22 - 11:12 am
JPMHC 2022
BeiGene
Ionis Pharmaceuticals
Roche
devices
AstraZeneca
Biogen
JPM 2022: Eli Lilly CEO mulls using Novo's double-branding trick on tirzepatide—one obesity, one diabetes
Fierce Pharma
Wed, 01/12/22 - 11:10 am
JPMHC 2022
Eli Lilly
Dave Ricks
tirzepatide
diabetes
obesity
Pfizer to Increase Manufacturing of Paxlovid COVID-19 Treatment and Have Omicron-Specific Vaccine Ready by March
Xtalks
Wed, 01/12/22 - 10:55 am
JPMHC 2022
Pfizer
Albert Bourla
Pharma CEOs
Paxlovid
COVID-19
Health tech M&A is heating up
Stat
Tue, 01/11/22 - 10:25 pm
M&A
devices
JPMHC 2022
DexCom
Teladoc
JPM 2022: Sanofi has designs on creating Big Pharma's 'strongest' immunology franchise, CFO says
Fierce Pharma
Tue, 01/11/22 - 10:18 pm
Sanofi
JPMHC 2022
M&A
Paul Hudson
JPM22, Day 2: Freenome passes $1B funding mark; Amgen spices things up with Arrakis; Sage touts double-duty anxiety drug
Fierce Biotech
Tue, 01/11/22 - 11:43 am
JPMHC 2022
Freenome
Amgen
Roche
ThermoFisher Scientific
Sarepta DMD Treatment Improves Motor Skills in Study Presented at JPM
BioSpace
Tue, 01/11/22 - 11:41 am
Sarepta Therapeutics
delandistrogene moxeparvovec
Duchenne Muscular Dystrophy
JPMHC 2022
JPM22, Day 2: Sanofi's dealmaking priorities, bluebird's gene therapy goals and more
Fierce Pharma
Tue, 01/11/22 - 11:37 am
JPMHC 2022
GSK
Sanofi
Bluebird Bio
JPM 2022: Bluebird CEO sees 'unfinished business' with Zynteglo in Europe, but scale-up needed first
Fierce Pharma
Tue, 01/11/22 - 11:31 am
Bluebird Bio
JPMHC 2022
Pharma CEOs
Europe
Zynteglo
JPM22: Pfizer's big bet on mRNA, Biogen 'proven wrong' on Aduhelm price and the next cell therapies
BioPharma Dive
Mon, 01/10/22 - 11:52 pm
JPMHC 2022
Pfizer
MRNA
Biogen
Aduhelm
cell therapy
JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff
Fierce Pharma
Mon, 01/10/22 - 11:49 pm
JPMHC 2022
Bristol Myers Squibb
Revlimid
patent cliffs
Opdivo
Eliquis
Reblozyl
Breyanzi
JPM 2022: Vertex's Trikafta holds the line as company lays groundwork for gene editing launch
Fierce Pharma
Mon, 01/10/22 - 11:44 pm
Vertex Pharmaceuticals
cystic fibrosis
JPMHC 2022
Trikafta
JPM 2022: New Johnson & Johnson CEO Duato points out 5 pipeline meds that can generate $5B+
Fierce Pharma
Mon, 01/10/22 - 11:33 pm
JPMHC 2022
JNJ
Pharma CEOs
consumer health
Joaquin Duato
#JPM22, Day 1: Bristol Myers Squibb's blockbuster losses of exclusivity, Novartis' spending plans and more
Fierce Pharma
Mon, 01/10/22 - 11:38 am
JPMHC 2022
Bristol Myers Squibb
Revlimid
Novartis
Moderna Therapeutics
JNJ
Trikafta
A late Christmas present for Allogene
EP Vantage
Mon, 01/10/22 - 11:27 am
Allogene
JPMHC 2022
FDA
CAR-T

Pages